PUBLICATION

Dianhydrogalactitol, a potential multitarget agent, inhibits glioblastoma migration, invasion, and angiogenesis

Authors
Jiang, X., Huang, Y., Wang, X., Liang, Q., Li, Y., Li, F., Fu, X., Huang, C., Liu, H.
ID
ZDB-PUB-170521-6
Date
2017
Source
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie   91: 1065-1074 (Journal)
Registered Authors
Keywords
Angiogenesis, Dianhydrogalactitol, Invasion, Migration, Multitarget agent
MeSH Terms
  • Animals
  • Cell Proliferation/drug effects
  • Vascular Endothelial Growth Factor A/metabolism
  • Matrix Metalloproteinase 2/metabolism
  • Antineoplastic Agents/pharmacology*
  • Vascular Endothelial Growth Factor Receptor-2/metabolism
  • Proto-Oncogene Proteins/metabolism
  • Cell Line, Tumor
  • Glioblastoma/drug therapy*
  • Glioblastoma/metabolism
  • Neovascularization, Pathologic/drug therapy*
  • Neovascularization, Pathologic/metabolism
  • Zebrafish
  • Signal Transduction/drug effects
  • Cell Line
  • Cell Movement/drug effects*
  • Angiogenesis Inhibitors/pharmacology*
  • Humans
  • Neoplasm Invasiveness/pathology*
  • Dianhydrogalactitol/pharmacology*
  • Human Umbilical Vein Endothelial Cells/drug effects
  • Human Umbilical Vein Endothelial Cells/metabolism
(all 22)
PubMed
28525947 Full text @ Biomed. Pharmacother.
CTD
28525947
Abstract
The complexity of cancer has led to single-target agents exhibiting lower-than-desired clinical efficacy. Drugs with multiple targets provide a feasible option for the treatment of complex tumors. Multitarget anti-angiogenesis agents are among the new generation of anticancer drugs and have shown favorable clinical efficacy. Dianhydrogalactitol (DAG) is a chemotherapeutic agent for chronic myeloid leukemia and lung cancer. Recently, it has been tested in phase II trials of glioblastoma treatment; however, mechanisms of DAG in glioblastoma have not been elucidated. Here we show that DAG could inhibit the migration and invasion of U251 cell line by inhibiting matrix metalloproteinase-2 (MMP2) expression. Furthermore, DAG could also inhibit tumor angiogenesis in vitro as well as in the zebrafish model. Mechanistic studies reveal that DAG inhibited both VEGFR2 and FGFR1 pathways. Our results suggest that DAG may be a potential multitarget agent that can inhibit tumor migration, invasion, and angiogenesis, and the anti-angiogenic effects may be involved in dual-suppression VEGF/VEGFR2 and FGF2/FGFR1 signal pathways.
Genes / Markers
Figures
Figure Gallery (1 images)
Show all Figures
Expression
Phenotype
No data available
Mutations / Transgenics
No data available
Human Disease / Model
No data available
Sequence Targeting Reagents
No data available
Fish
No data available
Antibodies
No data available
Orthology
No data available
Engineered Foreign Genes
No data available
Mapping
No data available
Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Citation
Jiang, X., Huang, Y., Wang, X., Liang, Q., Li, Y., Li, F., Fu, X., Huang, C., Liu, H. (2017) Dianhydrogalactitol, a potential multitarget agent, inhibits glioblastoma migration, invasion, and angiogenesis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 91:1065-1074.